---
title: "Mingchen Health released its performance for the first three quarters, with a net profit attributable to the parent company of 42.5498 million yuan, a year-on-year decrease of 56.03%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263098401.md"
description: "According to the Zhitong Finance APP, Mingchen Health released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.079 billion yuan, a year-on-year increase of 9.56%. The net profit attributable to shareholders of the listed company was 42.5498 million yuan, a year-on-year decrease of 56.03%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 41.2171 million yuan, a year-on-year decrease of 57.03%"
datetime: "2025-10-28T13:08:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263098401.md)
  - [en](https://longbridge.com/en/news/263098401.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263098401.md)
generator: "portal-rs"
---

# Mingchen Health released its performance for the first three quarters, with a net profit attributable to the parent company of 42.5498 million yuan, a year-on-year decrease of 56.03%

According to the Zhitong Finance APP, Mingchen Health (002919.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.079 billion yuan, a year-on-year increase of 9.56%. The net profit attributable to shareholders of the listed company was 42.5498 million yuan, a year-on-year decrease of 56.03%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 41.2171 million yuan, a year-on-year decrease of 57.03%

### Related Stocks

- [002919.CN](https://longbridge.com/en/quote/002919.CN.md)

## Related News & Research

- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [Apple Releases New Polishing Cloth](https://longbridge.com/en/news/296925479.md)
- [Polska Grupa Hutnicza discloses related-party share transaction under MAR rules](https://longbridge.com/en/news/296917492.md)
- [22:05 ETKutta Technologies' KTAC Controller Approved for DCMA Blue List](https://longbridge.com/en/news/296974738.md)
- [21:24 ETCaliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment](https://longbridge.com/en/news/296970484.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**